Mycoplasma Genitalium Testing & Treatment Springfield Lakes: Complete Guide 2025
Concerned about Mycoplasma genitalium? This emerging sexually transmitted infection is increasingly recognized as a significant cause of urogenital disease, requiring specialized testing and careful antibiotic management due to rising resistance rates.
Understanding Mycoplasma Genitalium
Mycoplasma genitalium (MG) is a small bacterial pathogen that causes urethritis, cervicitis, and pelvic inflammatory disease. First identified in 1981, it has emerged as an important sexually transmitted infection with increasing prevalence and concerning antibiotic resistance patterns.
Mycoplasma Genitalium in Australia
| Epidemiological Data | Australian Statistics | Clinical Significance |
|---|---|---|
| Prevalence in STI clinics | 15-25% of NGU cases | Major cause of urethritis |
| General population | 1-3% sexually active adults | Underdiagnosed infection |
| Resistance rates | 40-60% macrolide resistance | Treatment challenges |
| Co-infection rates | 20-30% with chlamydia/gonorrhea | Complex management |
Transmission and Risk Factors
Primary Transmission:
- Sexual contact (vaginal, anal, oral)
- Multiple sexual partners
- Concurrent STI infections
- Young age (15-25 years)
Risk Factors:
- New sexual partners
- Inconsistent condom use
- Previous STI history
- High-risk sexual behaviors
Clinical Presentation
Men – Urethritis and Complications
| Symptom | Prevalence | Characteristics | Complications |
|---|---|---|---|
| Urethral discharge | 60-80% | Clear to purulent | Chronic urethritis |
| Dysuria | 70-90% | Burning urination | Prostatitis |
| Urethral itching | 40-60% | Mild to moderate | Epididymitis |
| Asymptomatic | 20-40% | No symptoms | Ongoing transmission |
Women – Cervicitis and PID
| Manifestation | Frequency | Presentation | Long-term Risks |
|---|---|---|---|
| Cervicitis | 30-50% | Mucopurulent discharge | Chronic inflammation |
| Urethritis | 20-40% | Dysuria, frequency | Recurrent UTIs |
| PID | 10-20% | Pelvic pain, fever | Infertility, ectopic pregnancy |
| Asymptomatic | 50-70% | No symptoms | Untreated complications |
Diagnostic Testing
Testing Methods and Accuracy
| Test Type | Sensitivity | Specificity | Sample Type | Turnaround Time |
|---|---|---|---|---|
| NAAT (PCR) | 95-99% | 98-100% | Urine, swab | 1-3 days |
| Multiplex PCR | 90-95% | 95-99% | Urine, swab | 1-2 days |
| Culture | 50-70% | 100% | Swab only | 7-14 days |
| Serology | Variable | Low | Blood | Not recommended |
When to Test for Mycoplasma Genitalium
Testing Indications:
- Persistent urethritis – after chlamydia/gonorrhea treatment
- Recurrent urethritis – multiple episodes
- PID cases – comprehensive STI screening
- Partner notification – sexual contacts of positive cases
- High-risk populations – MSM, multiple partners
Specimen Collection:
- Men: First-void urine or urethral swab
- Women: Vaginal swab (self-collected or clinician-collected)
- Rectal/throat samples: Not routinely recommended
Treatment Protocols
First-Line Treatment
| Clinical Scenario | Antibiotic | Dosage | Duration | Efficacy |
|---|---|---|---|---|
| Uncomplicated infection | Doxycycline | 100mg BD | 7 days | 85-95% |
| Suspected resistance | Azithromycin | 1g day 1, 500mg days 2-5 | 5 days | 60-80% |
| Complicated infection | Doxycycline | 100mg BD | 14 days | 90-95% |
| Treatment failure | Moxifloxacin | 400mg daily | 7-10 days | 90-95% |
Resistance-Guided Treatment
Macrolide Resistance Testing:
- Available in specialized laboratories
- Guides treatment decisions
- Important for treatment failures
- Helps preserve fluoroquinolone efficacy
Treatment Algorithm:
- First-line: Doxycycline 100mg BD × 7 days
- If resistance suspected: Extended doxycycline or moxifloxacin
- Treatment failure: Resistance testing + moxifloxacin
- Persistent infection: Specialist referral
Management of Complications
Pelvic Inflammatory Disease
Clinical Presentation:
- Lower abdominal pain
- Abnormal vaginal discharge
- Irregular bleeding
- Fever and systemic symptoms
Treatment Approach:
- Broad-spectrum antibiotics – cover multiple pathogens
- Extended duration – 14 days minimum
- Partner treatment – essential for cure
- Follow-up – ensure symptom resolution
Chronic/Recurrent Urethritis
Management Strategy:
- Exclude other causes – comprehensive testing
- Resistance testing – guide antibiotic choice
- Extended treatment – longer courses may be needed
- Partner management – treat all recent partners
Partner Management
Contact Tracing and Treatment
Notification Period:
- 60 days prior to symptom onset
- Current sexual partners – regardless of timing
- High-risk contacts – multiple partners, sex workers
Partner Treatment:
- Empirical treatment – without testing
- Same regimen – as index case
- Abstinence – until treatment completion
- Follow-up – ensure adherence
Prevention Counseling
Risk Reduction:
- Consistent condom use – primary prevention
- Partner reduction – limit concurrent partners
- Regular screening – high-risk individuals
- Prompt treatment – of diagnosed infections
Antimicrobial Resistance
Current Resistance Patterns
| Antibiotic Class | Resistance Rate | Mechanism | Clinical Impact |
|---|---|---|---|
| Macrolides | 40-60% | 23S rRNA mutations | Treatment failure |
| Fluoroquinolones | 5-15% | DNA gyrase mutations | Limited options |
| Tetracyclines | <5% | Efflux pumps | Still effective |
Resistance Prevention
Stewardship Principles:
- Appropriate testing – confirm diagnosis before treatment
- Targeted therapy – resistance-guided when possible
- Complete courses – ensure full treatment duration
- Avoid monotherapy – consider combination approaches
Special Populations
Pregnancy and Mycoplasma Genitalium
Maternal Risks:
- Preterm birth – increased risk
- Chorioamnionitis – intrauterine infection
- Postpartum endometritis – puerperal sepsis
Treatment in Pregnancy:
- Azithromycin – preferred agent
- Avoid doxycycline – teratogenic risk
- Extended courses – may be needed
- Partner treatment – essential
HIV Co-infection
Clinical Considerations:
- Increased susceptibility – to MG infection
- Enhanced transmission – HIV acquisition/transmission
- Treatment challenges – drug interactions
- More frequent screening – every 3-6 months
Innovation and Future Directions
Diagnostic Advances
Point-of-Care Testing:
- Rapid molecular tests – results in 30-60 minutes
- Resistance detection – simultaneous resistance testing
- Multiplexed platforms – test multiple STIs
- Cost-effective screening – broader testing access
Treatment Development
Novel Antibiotics:
- Pristinamycin – promising alternative
- Lefamulin – new mechanism of action
- Combination therapy – synergistic approaches
- Anti-biofilm agents – address persistence
Vaccine Research
Vaccine Development:
- Antigen identification – surface proteins
- Adjuvant optimization – enhance immune response
- Clinical trials – early phase studies
- Population impact – modeling studies
Long-term Outcomes
Reproductive Health Impact
Female Complications:
- Tubal infertility – 10-15% with PID
- Ectopic pregnancy – 6-10 fold increased risk
- Chronic pelvic pain – 20-30% with PID
- Recurrent infections – treatment failures
Male Complications:
- Chronic prostatitis – persistent symptoms
- Epididymitis – testicular complications
- Male infertility – sperm quality effects
- Urethral stricture – rare complication
Quality of Life
Psychological Impact:
- Anxiety – about fertility and transmission
- Depression – chronic symptoms
- Relationship stress – partner notification
- Sexual dysfunction – fear and discomfort
Health Hub Springfield Lakes: Expert Mycoplasma Genitalium Care
Comprehensive Testing Services
- Specialized PCR testing – high sensitivity and specificity
- Resistance testing – guide treatment decisions
- Comprehensive STI panels – rule out co-infections
- Same-day results – rapid molecular testing available
Evidence-Based Treatment
- Current guidelines – following Australian recommendations
- Resistance-guided therapy – optimize treatment success
- Partner management – comprehensive contact tracing
- Follow-up testing – ensure treatment success
Specialized Care
- Complicated infections – PID and chronic cases
- Treatment failures – specialist consultation
- Pregnancy management – safe treatment options
- HIV co-infection – coordinated care
Book Your Confidential Consultation
- Online booking: Available 24/7 at healthhubspringfieldlakes.com.au/
- Phone booking: Call +61 7 3778 4888
- Same-day appointments: Available for urgent cases
- Bulk billing: Available for eligible patients
- Complete confidentiality: Private, professional care
Address: 18 Springfield Lakes Blvd, Springfield Lakes QLD 4300
Your trusted partner for comprehensive Mycoplasma genitalium testing and treatment.
Medical References
- Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. Australian STI Management Guidelines. Sydney: ASHM; 2024.
- Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30(10):1650-1656.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
- Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment. J Infect Dis. 2017;216(suppl_2):S412-S419.
- Australian Government Department of Health. National Notifiable Diseases Surveillance System Annual Report 2023. Commonwealth of Australia; 2024.
Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice. Mycoplasma genitalium testing and treatment require proper medical evaluation. If you have symptoms or concerns, please consult a healthcare professional promptly.